TARS
Tarsus Pharmaceuticals, Inc.NASDAQHealthcareAs of 2026-04-06
Valuation
View DetailsP/E (TTM)
—
PEG
—
P/B
8.74
P/S
6.61
EV/EBITDA
-51.80
DCF Value
$-432.41
FCF Yield
-0.7%
Div Yield
0.0%
Margins & Returns
Gross Margin
89.6%
Operating Margin
-15.7%
Net Margin
-14.7%
ROE
-19.6%
ROA
-12.0%
ROIC
-16.6%
Financials
View All| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 2025 | $151.7M | $-8.4M | $-0.20 |
| FY 2025 | $451.4M | $-66.4M | $-1.59 |
| Q3 2025 | $118.7M | $-12.6M | $-0.30 |
| Q2 2025 | $102.7M | $-20.3M | $-0.48 |
Analyst Ratings
View AllTrading Activity
Insider Trades
View AllCompany Info
Sector
Healthcare
Industry
—
Country
US
Exchange
NASDAQ
Beta
0.63
Tarsus Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for ophthalmic conditions. Its lead product candidate is TP-03, a novel therapeutic that is in Phase III for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. The company is also developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other diseases. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California.